Brief: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

Veru

24/06/2025 13:36

June 24 (Reuters) - Veru Inc VERU.O:

VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION

VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION

VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION

VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS

VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM

VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM

Source text: ID:nGNXbbvp7V

Further company coverage: VERU.O

 ((Reuters.Briefs@thomsonreuters.com;))